New Oral Weight Loss Drugs: Where Are We and What's Next?
Jun 5, 2024 · The company also announced that the US Food and Drug Administration has approved an expansion of the trial's protocol to investigate the contribution of circadian effects in weight loss treatment.
The Truth About Compounded GLP-1s That Doctors Need to Know
Mar 26, 2024 · The manufacturers of the two FDA-approved drugs, Novo Nordisk and Eli Lilly (tirzepatide, marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes), are struggling to meet the ...
FDA Approves Liraglutide ( Saxenda ) for Weight Loss - Medscape
Dec 23, 2014 · The FDA approved liraglutide for weight loss under a risk evaluation and mitigation strategy consisting of a communication plan to inform healthcare providers about the serious risks of the drug.
Quick Takes: The 5 FDA-Approved Obesity Drugs - Medscape
Mar 2, 2017 · The US Food and Drug Administration (FDA) has approved five medicines for long term use, including four relatively new drugs—the first drugs approved for obesity in 13 years—with solid data on ...
FDA Approves Semaglutide for Cardiovascular Risk Reduction
Mar 8, 2024 · The US Food and Drug Administration (FDA) has approved the anti- obesity drug semaglutide 2.4 mg injection (Wegovy) for reducing cardiovascular risk in adults with overweight or obesity and ...
Docs Weigh In on Insurance Coverage for Obesity Medications
Oct 13, 2023 · In a statement issued on May 31, 2023, the FDA cited reports of adverse events associated with the use of compounded weight loss drugs as a lower-cost alternative to the approved product.
Major Breakthrough in Weight Loss With Semaglutide? - Medscape
Nov 12, 2020 · The larger weight losses (over 20% in 36% of patients) will mean that more patients with obesity will be able to achieve a weight loss they are satisfied with, says the lead of a phase 3 trial.
FDA Approves 'Game Changer' Semaglutide for Weight Loss
Jun 4, 2021 · The mean 15% weight loss at 68 weeks is nearly twice what is seen with other FDA-approved anti-obesity medications, he noted, and moreover, 70% of patients taking semaglutide lost at least 10% of ...
How Are Endos Handling Weight-Loss Drug Shortages? - Medscape
Mar 5, 2024 · The Alliance for Pharmacy Compounding continues to argue that the compounded weight-loss drugs are legitimate options, claiming that FDA Commissioner Robert Califf conflated compounded drugs and ...
FDA Approves Tirzepatide for Treating Obesity - Medscape
Nov 8, 2023 · The US Food and Drug Administration (FDA) has approved tirzepatide for chronic weight management in adults with obesity or overweight. Eli Lilly & Company will market tirzepatide injections for ...